MedPath

Tucidinostat

Generic Name
Tucidinostat
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C22H19FN4O2
CAS Number
1616493-44-7
Unique Ingredient Identifier
87CIC980Y0
Indication

Investigated for use/treatment in cancer/tumors (unspecified).

Associated Conditions
-
Associated Therapies
-

A Prospective Clinical Study of Bridging alloHSCT After Treatment With Obinutuzumab in Combination With Chidamide and Venetoclax in RR Ph-ALL and B-cell Lymphoma Patients

Phase 1
Not yet recruiting
Conditions
Acute Lymphoblastic Leukemia
Interventions
First Posted Date
2023-10-17
Last Posted Date
2023-11-02
Lead Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Target Recruit Count
42
Registration Number
NCT06087419

Low-dose Chidamide Maintenance Therapy After Allo-HSCT for T-cell Acute Lymphoblastic Leukemia or T-cell Lymphomas

Phase 2
Recruiting
Conditions
T Lymphoblastic Leukemia/Lymphoma
Interventions
First Posted Date
2023-08-15
Last Posted Date
2023-08-15
Lead Sponsor
Zhejiang University
Target Recruit Count
44
Registration Number
NCT05991973
Locations
🇨🇳

The First Hospital of Zhejiang Medical Colleage Zhejiang University, Hangzhou, Zhejiang, China

Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer

Phase 2
Recruiting
Conditions
HR+/HER2- Advanced Breast Cancer
Targeted Therapy
Interventions
Drug: Everolimus
Drug: Chidamide
Drug: Endocrine therapy
Drug: Ovarian function suppression(OFS)
First Posted Date
2023-08-09
Last Posted Date
2023-08-09
Lead Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Target Recruit Count
102
Registration Number
NCT05983107
Locations
🇨🇳

National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China

A Retrospective Clinical Study on the First-line Maintenance Treatment of PTCL With Chidamide.

Recruiting
Conditions
PTCL
First Posted Date
2023-08-01
Last Posted Date
2023-08-01
Lead Sponsor
The First Affiliated Hospital with Nanjing Medical University
Target Recruit Count
200
Registration Number
NCT05967949
Locations
🇨🇳

Hematological Department, People's Hospital of Jiangsu Province, Nanjing, Jiangsu, China

Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma

Phase 2
Recruiting
Conditions
Peripheral T Cell Lymphoma
Epigenetic Repression
Interventions
First Posted Date
2023-07-25
Last Posted Date
2024-12-30
Lead Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Target Recruit Count
37
Registration Number
NCT05958719
Locations
🇨🇳

Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China

Study of Selinexor Combined With Chidamide in Relapsed/Refractory Acute Leukemia (AML) Patients

Phase 2
Recruiting
Conditions
Acute Myeloid Leukemia (Relapsed/Refractory)
Interventions
First Posted Date
2023-07-19
Last Posted Date
2023-07-19
Lead Sponsor
The First Affiliated Hospital of Soochow University
Target Recruit Count
42
Registration Number
NCT05951855
Locations
🇨🇳

The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China

A Study of Chidamide Plus Endocrine in Maintenance Treatment of HR+/HER2- Breast Cancer After First-line Chemotherapy

Not Applicable
Recruiting
Conditions
HR Positive HER2 Negative Advanced Breast Cancer
Interventions
First Posted Date
2023-06-06
Last Posted Date
2023-06-06
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
60
Registration Number
NCT05890287
Locations
🇨🇳

天津市肿瘤医院, Tianjin, China

Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)

Phase 2
Recruiting
Conditions
Relapsed or Refractory Peripheral T-cell Lymphoma
Interventions
First Posted Date
2023-04-27
Last Posted Date
2024-02-26
Lead Sponsor
Great Novel Therapeutics Biotech & Medicals Corporation
Target Recruit Count
33
Registration Number
NCT05833724
Locations
🇨🇳

Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan

🇨🇳

National Taiwan University Hospital, Taipei, Taiwan

🇨🇳

Chang Gung Memorial Hospital, Kaohsiung, Kaohsiung, Taiwan

and more 2 locations

Chidamide, Azacitidine Combined With GM Regimen for Relapsed and Refractory DLBCL Patients

Phase 2
Recruiting
Conditions
Diffuse Large B-Cell Lymphoma
Interventions
Drug: Chidamide
Drug: Azacitidine
Biological: obinutuzumab
Drug: Liposomal mitoxantrone
First Posted Date
2023-04-21
Last Posted Date
2023-04-21
Lead Sponsor
The First Affiliated Hospital of Soochow University
Target Recruit Count
23
Registration Number
NCT05823701
Locations
🇨🇳

the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China

© Copyright 2025. All Rights Reserved by MedPath